Skip to main content
Premium Trial:

Request an Annual Quote

Parkinson's UK Seeks Protein Biomarkers for Diagnosing, Tracking Disease

NEW YORK (GenomeWeb News) – The British non-profit Parkinson's UK plans to provide £750,000 ($1.2 million) for research to find protein biomarkers for diagnosing and measuring the progress of Parkinson's disease.

The new grant, which is available to researchers within and outside the UK, will fund a study that uses a proteomics-based approach to identify biomarkers in blood or cerebrospinal fluid, Parkinson's UK said in a funding announcement late last week.

These markers would enable better and more accurate diagnosis of Parkinson's, or would be used to assess the efficacy of new therapies, such as neuroprotective or neurorestorative drugs.

Results from the three-year study will be integrated into the non-profit's Tracking Parkinson's longitudinal clinical study, which aims to enlist thousands of patients through a network of more than 40 study centers across the UK.

Parkinson's UK said that universities, research institutes, or hospital trusts may apply for the funding, and it will consider projects that involve collaborations between the academic and biotech business sector.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.